CLSD Valuation

Clearside Biomedical Inc

Add to Watchlist

Advanced Chart

0.852

-0.013(-1.500%)

Overview
Forecast
Valuation

CLSD Relative Valuation

CLSD's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CLSD is overvalued; if below, it's undervalued.

Historical Valuation

Clearside Biomedical Inc (CLSD) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of 105.74. The fair price of Clearside Biomedical Inc (CLSD) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 0.85 USD , Clearside Biomedical Inc is Undervalued By Fair.

Relative Value

Fair Zone

+Inf-+Inf

Current Price：0.85

Fair

Undervalued

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

-1.69

P/B

Median3y

0.58

Median5y

5.07

0.00

FCF Yield

Median3y

-23.02

Median5y

-17.58

Competitors Valuation Multiple

The average P/S ratio for CLSD's competitors is 0.45, providing a benchmark for relative valuation. Clearside Biomedical Inc Corp (CLSD) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of -95.18%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

CLSD.O

Clearside Biomedical Inc

Loss

Average P/S: 0.45

-95.18%